Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat

Blood (2022) 140 (Supplement 1): 577–578.

https://doi.org/10.1182/blood-2022-156389

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of the Francophone Society for Stem Cell Transplantation and Cell Therapy

Regis Peffault De Latour, Matthieu Resche-Rigon, MD PhD, Didier Blaise, Johan Maertens, MD, Patrice Ceballos, MD, Patrice Chevallier, MD, Edouard Forcade, MD, Anne Huynh, MD, Pierre Simon Rohrlich, Helene Labussiere-Wallet, MD, Jacques-Olivier Bay, MD PhD, Yves Chalandon, MD PhD, Gerard Socie, MD PhD, Marie Thérèse Rubio, MD

Blood (2018) 132 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2018-99-111710

Published: 2018

Journal Articles

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Juliette Soret-Dulphy, MD, Matthieu Resche-Rigon, MD PhD, Francoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Valérie Rolland-Neyret, Claude Capron, Sylvie Chevret, MD PhD, Stephane Giraudier, MD PhD, Bruno Cassinat, PharmD, PhD

Blood (2018) 132 (Supplement 1): 581.

https://doi.org/10.1182/blood-2018-99-110785

Published: 2018

Journal Articles

Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia

Blood (2018) 132 (Supplement 1): 1298.

https://doi.org/10.1182/blood-2018-99-113359

Published: 2018

Journal Articles

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC

Pedro H Prata, MD, Matthieu Resche-Rigon, MD PhD, Didier Blaise, Gérard Socié, MD PhD, Pierre Simon Rohrlich, Noel-Jean Milpied, MD, Pascal Turlure, MD, Stephanie Nguyen, MD PhD, Anne Sirvent, MD, Claude-Eric Bulabois, MD, Eric Deconinck, MD PhD, Amandine Charbonnier, Patrice Chevallier, MD, Jacques-Olivier Bay, MD PhD, Benedicte Neven, MD, Charlotte Jubert, MD, Mohamad Mohty, MD PhD, Marie Thérèse Rubio, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2018-99-111610

Published: 2018

Journal Articles

Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT

Lucie Biard, MDMSc, Myriam Labopin, Annalisa Ruggeri, MD, Fabio Ciceri, MD, Johanna Tischer, Boris V Afanasyev, Professor, Domenico Pastore, Donald Bunjes, Gerhard Ehninger, MD, Dietrich W. Beelen, Prof. Dr. MD, Mohamad Mohty, MD PhD, Arnon Nagler, Matthieu Resche-Rigon, MD PhD

Blood (2016) 128 (22): 3488.

https://doi.org/10.1182/blood.V128.22.3488.3488

Published: 2016

Journal Articles

Quality of Life in Cancer Patients Undergoing Anticoagulant Treatment for Venous Thromboembolism: The Quavitec Study

Dominique Farge, MD PhD, Nicolas Falvo, MD, Matthieu Resche-Rigon, MD PhD, Toufek Berremili, MD, Francis Couturaud, MD PhD, Okba Bensaoula, MD, Lionel Védrine, MD, Isabelle Bonnet, MD, Denis Péré-Vergé, MD, Marie Coudurier, MD, Veronique Li, MD, Francis Cajfinger, MD

Blood (2016) 128 (22): 880.

https://doi.org/10.1182/blood.V128.22.880.880

Published: 2016

Journal Articles

Long-Term Prognostic Significance of Response in Hodgkin Lymphoma Before Autologous Stem Cell Transplantation :Results of the Prospective Multicenter H96 Trial by the GELA/SFGM-TC Study Group

David Sibon, MD, PhD, Matthieu Resche-Rigon, MD, PhD, Franck Morschhauser, Christophe Fermé, Isabelle Gaillard, MD, Ambroise Marcais, MD, Reda Bouabdallah, MD, Catherine Sebban, MD, Gilles Andre Salles, MD, PhD, Pauline Brice, MD

Blood (2011) 118 (21): 3070.

https://doi.org/10.1182/blood.V118.21.3070.3070

Published: 2011

Journal Articles

Estimating the Causal Effect of Some Exposure From Nonrandomized Studies: The Example of Reduced Intensity Conditioning (RIC) in Hematological Diseases.

Matthieu Resche-Rigon, Marie Robin, Regis Peffault de Latour, Sylvie Chevret, Gerard P Socie

Blood (2009) 114 (22): 3365.

https://doi.org/10.1182/blood.V114.22.3365.3365

Published: 2009

NARROW

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of the Francophone Society for Stem Cell Transplantation and Cell Therapy

Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis

Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC

Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT

Quality of Life in Cancer Patients Undergoing Anticoagulant Treatment for Venous Thromboembolism: The Quavitec Study

Long-Term Prognostic Significance of Response in Hodgkin Lymphoma Before Autologous Stem Cell Transplantation :Results of the Prospective Multicenter H96 Trial by the GELA/SFGM-TC Study Group

Estimating the Causal Effect of Some Exposure From Nonrandomized Studies: The Example of Reduced Intensity Conditioning (RIC) in Hematological Diseases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only